Retrospective correlation of 68 ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy

ConclusionsWe demonstrated a correlation between prostate tumor characteristics and PSMA tracer uptake. Patients with serum PSA  >  10 ng/mL, GS >  7, D’Amico high-risk group classification, and pelvic lymph node metastasis had significantly higher SUV than their counterparts. In addition, the primary tumor detection rate was higher in patients with serum PSA >  10 ng/mL and GS >  7.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research

Related Links:

This study investigated the performance of 68Ga-prostate-specific-membrane-antigen-11 positron-emission-tomography/computed-tomography for detecting prostate carcinoma in patients with rising prostate-specific-antigen after primary therapy. Six hundred sixty (660) patients with biochemical recurrence referred for positron-emission-tomography/computed-tomography with 68Ga-prostate-specific-membrane-antigen-11 were evaluated retrospectively. Prostate-specific-antigen-stratified cohorts of pathological scan results were analyzed, and relationships between prostate-specific-antigen kinetics and PSMA-positive tumor lesions were...
Source: Health Physics - Category: Radiology Tags: Papers Source Type: research
An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Our purpose was to evaluate the performance of 11C-choline PET/CT in detecting biochemically recurrent prostate cancer (PCa) in a large non-European cohort (in the context of emerging evidence for prostate-specific membrane antigen PET in this setting) and to map patterns of PCa recurrence. Methods: We retrospectively analyzed 11C-choline PET/CT scans from 287 patients who were enrolled in an imaging protocol based on rising prostate-specific antigen (PSA) levels (mean, 3.43 ng/mL; median, 0.94 ng/mL; range, 0.15–89.91 ng/mL) and suspected recurrent PCa. A total of 187 patients had undergone primary radical prostatec...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
ConclusionsIntegrated [68Ga]PSMA-11 PET/MRI provides a similarly high diagnostic performance for localization of recurrent PC as PET/CT. For the detection of local recurrences [68Ga]PSMA-11 PET/MRI is superior compared with [68Ga]PSMA-11 PET/CT.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
Conclusion: Our patient, diagnosed with recurrent prostate BCC after receiving a radical prostatectomy, responded to treatment with etoposide. Radical prostatectomy and radiotherapy should remain first-line therapy; however, etoposide may be an alternative second-line therapy when other options are not available. Consensus regarding treatment plans, and the molecular mechanisms behind prostate BBC, must be elucidated.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAn incidence of 0.1% in our study confirms the rarity of penile metastases of prostate cancer. Although rare, identification of prostate cancer penile metastases is important for appropriate treatment management and symptom ‐relief.
Source: Journal of Medical Imaging and Radiation Oncology - Category: Radiology Authors: Tags: Medical Imaging — Original Article Source Type: research
ung P Abstract PURPOSE: To report dosimetry, preliminary toxicity and health-related quality of life (HRQoL) outcomes of tumor-targeted dose-escalation delivered by integrated boost volumetric arc therapy (IB-VMAT) or MR-guided HDR brachytherapy (HDR) boost for prostate cancer. MATERIALS AND METHODS: Patients diagnosed with localized prostate cancer, with at least 1 identifiable intraprostatic lesion on multiparametric MRI (mpMRI) were enrolled in a prospective non-randomized phase II study. All patients received VMAT to the prostate alone (76 Gy in 38 fractions) plus a GTV boost: IB-VMAT (95Gy in 38 fraction...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
The objective of this article is to review published data on positron emission tomography combined with computed tomography as a tool for evaluating external radiotherapy for cancers. Data on positron emission tomography combined with computed tomography scans acquired at different times (during, after initial and after definitive [chemo-]radiotherapy, during post-treatment follow-up) in solid tumours (lung, head and neck, cervix, oesophagus, prostate and rectum) were collected and analysed. Recent recommendations of the National Comprehensive Cancer Network are also reported. Positron emission tomography combined with com...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
The objective of this study is to evaluate the safety and therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy (TAT) in metastatic castration resistant prostate cancer patients (mCRPC). Methods: The study has been approved by the Institute Ethics Committee (IEC:518). 28 mCRPC patients refractory to therapy options including first and second generation anti-androgen therapies, taxane-based chemotherapies, and 177Lu-PSMA-617 therapy were treated with 225Ac-PSMA-617 TAT (100 KBq/Kg body weight) at an interval of 8 weeks up to 7 cycles. The patients were treated from April 2018 to November 2019 with median follow-up d...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate: PSMA radioligand therapy Source Type: research
36Objectives: Due to a markedly immunosuppressive tumor microenvironment (TME), immunotherapy has had limited success in prostate cancer (PCa). Radiation therapy, which has shown to remodel the TME of irradiated tumors towards a more immune-susceptible phenotype even at low radiation doses of 2-3 Gy, is limited to the localized disease setting. Our goal is to demonstrate that systemically delivered targeted radionuclide therapy (TRT) using [90Y]Y-NM600 provides beneficial immunomodulatory effects that may enhance the response of PCa to immunotherapies. Methods: Male FVB mice bearing syngeneic prostate Myc-CaP tumor allogra...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Center for Therapy Excellence YIA Symposium Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Nuclear Medicine | PET Scan | Prostate Cancer | Study